Elite Pharmaceuticals, Inc. 165 Ludlow Avenue Northvale, NJ 07647 Tel: (201) 750-2646 January 7, 2008 AS FILED ON EDGAR AND - --------------------- VIA REGULAR U.S. MAIL - --------------------- Division of Corporation Finance Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Mail Stop 6010 Attn: Jeffrey Riedler Re: Elite Pharmaceuticals, Inc., Pre-Effective Amendment No. 1 to Registration Statement on Form S-3 Filed August 16, 2007 File No. 333-145502 Dear Mr. Riedler: On behalf of Elite Pharmaceuticals, Inc., a Delaware corporation ("Company"), please be informed that the undersigned has received and read your letter, dated August 23, 2007, with regard to the Registration Statement on Form S-3 filed with the Securities and Exchange Commission (the "Commission") on August 16, 2007. The Company acknowledges herewith, that: o the Company is responsible for the adequacy and accuracy of the disclosure in the filing; o staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and o the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Of course, if you should require any additional information or clarification, please do not hesitate to contact the undersigned at the telephone number given above. Securities and Exchange Commission January 7, 2008 Page 2 of 2 Your assistance in this matter is greatly appreciated. Thank you. Sincerely, /s/ Mark Gittelman Chief Financial Officer Elite Pharmaceuticals, Inc. cc: Bernard Berk, Chief Executive Officer and Chairman of the Board of Directors Elite Pharmaceuticals, Inc.